Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with rituximab and to see how well they work in treating patients with relapsed B-cell non-Hodgkin lymphoma.

Timeline

Start

2008-05

Primary completion

2009-01

Completion

2009-04

Outcome

Outcome not reported

Stopped (Enrollment): “Funding ended when only one subject enrolled and subject withdrew early.”

Drugs

Indications